Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.13% | 54.59% | 16.20% | 28.11% | 22.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.00% | -39.81% | -39.15% | -18.19% | -22.67% |
| Operating Income | -58.00% | 39.81% | 39.15% | 18.19% | 22.67% |
| Income Before Tax | -86.53% | 47.12% | 38.74% | 26.53% | 33.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.53% | 47.12% | 38.74% | 26.53% | 33.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.53% | 47.12% | 38.74% | 26.53% | 33.17% |
| EBIT | -58.00% | 39.81% | 39.15% | 18.19% | 22.67% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -81.36% | 53.81% | 47.52% | 37.13% | 41.87% |
| Normalized Basic EPS | -81.08% | 53.78% | 47.62% | 37.50% | 41.73% |
| EPS Diluted | -81.36% | 53.81% | 47.52% | 37.13% | 41.87% |
| Normalized Diluted EPS | -81.08% | 53.78% | 47.62% | 37.50% | 41.73% |
| Average Basic Shares Outstanding | 2.99% | 14.59% | 17.08% | 17.07% | 14.99% |
| Average Diluted Shares Outstanding | 2.99% | 14.59% | 17.08% | 17.07% | 14.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |